AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie (ABBV) has completed its acquisition of Aliada Therapeutics, strengthening its neuroscience pipeline with ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease currently in Phase 1 clinical trials. The acquisition brings two key assets: the anti-pyroglutamate amyloid beta antibody ALIA-1758, and a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system. This strategic move positions AbbVie to address the growing challenge of Alzheimer's disease, which affects millions globally and is becoming more prevalent with aging populations.
AbbVie (ABBV) ha completato l'acquisizione di Aliada Therapeutics, rafforzando il suo portafoglio nel settore neuroscientifico con ALIA-1758, una potenziale terapia modificante la malattia di classe migliore per la malattia di Alzheimer, attualmente in fase di sperimentazione clinica di Fase 1. L'acquisizione porta con sé due risorse chiave: l'anticorpo anti-piroglutamato dell'amiloide beta ALIA-1758 e una nuova tecnologia di attraversamento della barriera emato-encefalica (BBB) che migliora la somministrazione di farmaci mirati nel sistema nervoso centrale. Questa mossa strategica posiziona AbbVie per affrontare la crescente sfida della malattia di Alzheimer, che colpisce milioni di persone in tutto il mondo ed è in aumento con l'invecchiamento della popolazione.
AbbVie (ABBV) ha completado la adquisición de Aliada Therapeutics, fortaleciendo su cartera en neurología con ALIA-1758, una terapia potencialmente innovadora que modifica la enfermedad y que está en ensayos clínicos de Fase 1 para la enfermedad de Alzheimer. La adquisición incluye dos activos clave: el anticuerpo anti-piroglutamato beta-amiloide ALIA-1758 y una nueva tecnología para atravesar la barrera hematoencefálica (BBB) que mejora la entrega de medicamentos específicos en el sistema nervioso central. Este movimiento estratégico posiciona a AbbVie para afrontar el creciente desafío que representa la enfermedad de Alzheimer, que afecta a millones de personas en todo el mundo y es cada vez más prevalente con el envejecimiento de la población.
AbbVie (ABBV)는 Aliada Therapeutics의 인수를 완료하여 ALIA-1758과 함께 신경과학 파이프라인을 강화하였습니다. ALIA-1758은 현재 1상 임상시험 중인 알츠하이머병에 대한 최고의 질병 수정 치료제가 될 가능성이 있는 물질입니다. 이 인수에는 두 가지 주요 자산이 포함되어 있습니다: 항 피로글루탐산 아밀로이드 베타 항체 ALIA-1758과 표적 약물을 중추 신경계에 전달하는 데 도움을 주는 새로운 혈액-뇌 장벽(BBB) 통과 기술입니다. 이 전략적 조치는 AbbVie가 전 세계 수백만 명에게 영향을 미치는 알츠하이머병의 증가하는 도전에 대처하는 데 중요한 위치를 차지하도록 합니다.
AbbVie (ABBV) a finalisé l'acquisition de Aliada Therapeutics, renforçant son portefeuille en neurosciences avec ALIA-1758, une thérapie potentiellement innovante modifiant la maladie pour la maladie d'Alzheimer, actuellement en essais cliniques de Phase 1. Cette acquisition apporte deux actifs clés : l'anticorps anti-pyroglutamate d'amyloïde beta ALIA-1758 et une nouvelle technologie de passage de la barrière hémato-encéphalique (BBB) qui améliore la délivrance de médicaments ciblés dans le système nerveux central. Ce mouvement stratégique positionne AbbVie pour faire face au défi croissant de la maladie d'Alzheimer, qui touche des millions de personnes dans le monde et devient de plus en plus répandue avec le vieillissement de la population.
AbbVie (ABBV) hat die Akquisition von Aliada Therapeutics abgeschlossen und sein Portfolio im Bereich Neurowissenschaften mit ALIA-1758 gestärkt, einer potenziell erstklassigen krankheitsmodifizierenden Therapie für die Alzheimer-Krankheit, die sich derzeit in Phase-1-Klinischen Studien befindet. Diese Akquisition bringt zwei zentrale Vermögenswerte mit sich: den anti-pyroglutamatischen Amyloid-beta-Antikörper ALIA-1758 und eine neuartige Technologie zum Überqueren der Blut-Hirn-Schranke (BBB), die die Abgabe zielgerichteter Medikamente ins zentrale Nervensystem verbessert. Dieser strategische Schritt positioniert AbbVie, um der wachsenden Herausforderung der Alzheimer-Krankheit zu begegnen, die weltweit Millionen von Menschen betrifft und mit der alternden Bevölkerung immer häufiger wird.
- Acquisition of novel blood-brain barrier crossing technology enhancing CNS drug delivery capabilities
- Addition of ALIA-1758, a potential best-in-class Alzheimer's treatment to pipeline
- Expansion into growing Alzheimer's disease market
- ALIA-1758 still in early Phase 1 trials, indicating long development timeline ahead
- No disclosed financial terms or impact on immediate revenue
Insights
- Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities
Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS).
"Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age," said Dawn Carlson, M.D., M.P.H., vice president, neuroscience development at AbbVie. "With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform."
For additional background on the acquisition, please read the announcement press release here.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-aliada-therapeutics-302329026.html
SOURCE AbbVie
FAQ
What is ALIA-1758 and how does it treat Alzheimer's disease?
How will the Aliada Therapeutics acquisition impact ABBV's neuroscience pipeline?
What stage of development is ABBV's newly acquired Alzheimer's drug ALIA-1758?
What technology did ABBV acquire through the Aliada Therapeutics purchase?
